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A mutant antithrombin was isolated from the plasma of a patient with pulmonary embolism. The new protein, which 
accounted for 55% of the antithrombin, had decreased heparin affinity and contained two components when analysed 
on the basis of either charge or molecular mass. Sialidase and endo+&acetylglucosaminidase F treatment suggested 
that this heterogeneity was due to a partial glycosylation occurring at a new carbohydrate attachment sequence. Peptide 
mapping by reverse-phase HPLC showed that the abnormality involved the N-terminal tryptic peptide. Sequence analysis 
demonstrated that the underlying mutation was 7 Ile-+Asn which introduces a new Asn-Cys-Thr glycosylation sequence. 
This new oligosaccharide attachment site occupies the base of the proposed heparin-binding site, and the finding explains 
the consequent decrease in heparin affinity. 
Antithrombin mutant; Thromboembolism; Carbohydrate attachment; Heparin binding 
1. INTRODUCTION 
Antithrombin is the principal protease inhibitor 
of the coagulation cascade and requires activation 
by the sulphated oligosaccharide heparin [l]. The 
major circulatory form of the protein has a mole- 
cular mass of 58 kDa and contains four asparagine- 
linked oligosaccharide side chains [2]. The tertiary 
structure of antithrombin has been inferred from 
the known three-dimensional structure of ar-anti- 
trypsin with which it shares a 30% identity of se- 
quence [3,4]. 
We describe here the characterisation of a new, 
low-heparin-affinity variant, antithrombin Rouen- 
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III (7 Ile*Asn), from a patient with pulmonary 
embolism. This finding supports the previous con- 
clusions, based. on other functional variants and 
protein homologies, that heparin binds to a posi- 
tively charged surface extending from Arg 47 in the 
A helix and along the outer face of the D helix to 
Lys 133 [5]. 
2. MATERIALS AND METHODS 
2.1. Materials 
Sialidase type VI (C. perfringens) was obtained from Sigma. 
Endo@-N-acetylglucosaminidase F (Endo F, F. meningosep- 
ticum) was obtained from New England Nuclear. 
2.2. Antithrombin measurements in plasma 
Antithrombin concentration was determined by Laurel1 elec- 
troimmunoassay [5]. Functional studies were carried out using 
synthetic chromogenic substrates of thrombin (IIa) and factor 
Xa. Progressive anti-IIa activity was assayed with S2232 (Kabi, 
Flow-Puteaux, France) and human IIa [7], while progressive 
anti-Xa activity was evaluated using CBS 3139 (Serbio-Asnieres, 
France) [8]. Antithrombin activity in the presence of heparin or 
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purified heparan sulphate was evaluated using bovine thrombin 
and substrate CBS 3447 as detailed in [5]. Anti-Xa activity was 
evaluated in the presence of both heparin and synthetic pen- 
tasaccharide (IC 851589, Institut Choay, Paris) using bovine 
factor Xa and substrate CBS 3139 as described [5]. Results are 
expressed as a percentage of a pool of control plasma from 20 
normal individuals. 
2.3. Fractionation of antithrombin 
Typically, 1 ml of 5 mM CaClz and 1 ml of 10% dextran 
sulphate were added to ,100 ml plasma. The supernatant was ap- 
plied to a 1.5 x 25 cm column of heparin-Sepharose equilibrated 
in 50 mM Tris-HCl, 10 mM citrate, pH 7.4 [5]. The column was 
eluted with a linear gradient o 1.3 M NaCl in the same buffer. 
2.4. Peptide mapping 
Antithrombin was carboxyamidomethylated in 8 M urea [9] 
and digested with trypsin [lo]. Reverse-phase HPLC mapping 
was carried out using a Waters 8 mm inner diameter adial com- 
pression cartridge with a 10/m C-18 packing. The initial solvent 
(A) was 49 mM KHzP04 adjusted to pH 2.9 with orthophos- 
phoric acid, while solvent B consisted of a 50: 50 mixture of A 
in acetonitrile [lo]. The flow rate was 1.5 ml/min and a linear 
gradient was run from 3 to 67% B over 46 min and then to 100% 
B over the next 8 min. Usually, 0.1 mg digest (1.7 nmol) was ap- 
plied per run. Peaks were collected, dried, and the insoluble 
phosphate residue was extracted with 20 ,ul of 60% ethanol to 
recover peptide material [ 111. 
2.5. Structural studies 
Peptides were hydrolysed (110°C for 16 h) under vacuum, us- 
ing vapour from 6 M HCl/ 1% phenol [ 121. Phenylthiocarbamyl 
derivatives of the amino acids were quantified by reverse-phase 
HPLC using a Waters Nova pat column [13]. Protein sequences 
were determined using an Applied Biosystems 475 A sequencer; 
the PTH amino acids were identified by HPLC. 
3. RESULTS 
3.1. Case history 
The propositus was a 60-year-old women who 
developed a massive pulmonary embolism 10 days 
after total hip replacement. The embolism oc- 
curred during an episode of severe heparin-induced 
thrombocytopenia. A variant antithrombin was 
diagnosed several weeks later and was also found in 
the woman’s daughter (table 1). Both mother and 
daughter had normal antigenic levels of antithrom- 
bin, and normal progressive anti-Ila and anti-Xa 
activity. However, there was impairment of activa- 
tion of antithrombin by heparin, heparan sulphate 
and by the synthetic pentasaccharide (table 1). 
These data suggested the (heterozygous) presence 
of a variant form of antithrombin with a defect in 
the heparin-binding domain. 
Table 1 
Antithrombin levels in the propositus’s and daughter’s plasma 
Propo- Daughter Normal 
situs range 
Antithrombin antigen 105 130 80-120 
Progressive anti-Da activity 115 105 80-120 
Progressive anti-Xa activity 93 93 78-l 14 
Heparin cofactor activity 
(anti-IIa) 66 65 82-l 18 
Heparan sulphate cofactor 
activity (anti-IIa) 70 60 84-120 
Heparin cofactor activity 
(anti-Xa) 70 75 82-l 16 
Pentasaccharide cofactor 
activity (anti-Xa) 60 68 84-116 
Average of three separate plasma samples expressed as % of 
control plasma 
3.2. Isolation and characterisation 
Chromatography of 100 ml plasma on heparin- 
Sepharose gave two well-resolved peaks of an- 
tithrombin. One eluted at 0.48 M NaCl, the other 
eluting in the position of normal antithrombin at 
0.85 M NaCl. The low-heparin-affinity antithrom- 
bin was present in a slight excess over the product 
of the normal gene when measured antigenically 
and gravimetrically (table 2). The purified abnor- 
mal antithrombin retained normal progressive anti- 
IIa activity but showed negligible activation by 
either heparin or the synthetic pentasaccharide 
(table 2). 
The low-heparin-affinity antihrombin migrated 
as two bands on agarose gel electrophoresis, both 
bands reacting with antisera against antithrombin 
(fig.1, lanes 3,9). The position of the more anodal 
band indicated an increase of two net negative 
Table 2 
Antithrombin levels in normal and abnormal fractions 
separated by heparin-Sepharose chromatography 
Abnormal Normal 
fraction fraction 
Yield from 100 ml plasma (mg) 6.6 5.9 
Antithrombin antiget? .60 40 
Progressive anti-IIa activitya 50 35 
Heparin cofactor activity (anti-IIa)” 5 45 
Pentasaccharide cofactor activity 
(anti-Xa)* <5 42 
a Results expressed as % of control plasma 
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Fig.1. Agarose gel electrophoresis, pH 8.6. (1) Serum control. 
(2) Purified antithrombin from pooled normal plasma. (3) 
Purified low-heparin-affinity fraction from propositus. (4) 
Normal antithrombin from propositus. (5,7) Normal fraction 
after 1 and 20 h incubation, respectively, with sialidase. (6,8) 
Low-heparin-affinity fraction after 1 and 20 h incubation with 
sialidase. Antithrombin (1.5 mg/ml) was incubated (20°C) with 
5% (w/w) sialidase in 50 mM acetate buffer, pH 5.5/5 mM 
CaC12. (9,lO) Immunofixation of 3 and 4, respectively, with 
anti-antithrombin antisera. 
charges, while the cathodal band had no formal in- 
crease in charge, running only marginally but con- 
sistently ahead of normal antithrombin. The pro- 
portion of the two low-heparin-affinity com- 
ponents varied from preparation to preparation 
and, indeed, the fast component disappeared on 
storage of the purified solution for more than 24 h. 
The low-heparin-affinity material was heterogene- 
ous with respect to molecular mass as well as 
charge. On SDS-polyacrylamide gel electrophoresis 
in both the presence and absence of P-mercapto- 
ethanol, this material ran as two bands, one co- 
migrating with normal antithrombin at 58 kDa, 
and the other at 2.5 kDa higher (fig.2). The propor- 
tion of these components did not alter, and solu- 
tions could be stored for several days without 
change in the pattern. 
Sialidase treatment would be expected to remove 
eight negatively charged sialic acid residues from 
antithrombin and in the process, reduce its mole- 
cular mass by approx. 2.5 kDa. On digestion with 
sialidase, both components of the low-heparin- 
affinity antithrombin lost negative charge to run as 
a single band with a mobility similar to that of 
asialo-antithrombin A on agarose gel electro- 
phoresis (fig.1). However, the molecular mass dif- 
ference between the two low-heparin-affinity com- 
ponents was retained on this treatment with sialid- 
i.5 : 5,,.?$’ 2 34 1 234567 
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Fig.2. SDS-polyacrylamide gel (10%) electrophoresis in the 
presence of ,&mercaptoethanol. (A) Effect of sialidase. (1.3) 
Normal antithrombin component before and after 1 h incu- 
bation with sialidase, respectively. (2,4) Low-heparin-affinity 
antithrombin before and after sialidase treatment. (B) Effect of 
endo F. (1) Marker of antithrombin p which lacks one of the 
four oligosaccharide side chains [14]. (2) Normal antithrombin 
from propositus. (3) Low-heparin-affinity antithrombin. (4,6) 
Normal antithrombin after 20 and 48 h incubation with endo F. 
(5,7) Low-heparin affinity antithrombin after 20 and 48 h 
incubation with endo F. Arrow shows position of fully 
glycosylated antithrombin while (- ) indicates successive 
removal of four oligosaccharide side chains. 1 ~1 endo F was 
added to 25 pg antithrombin in 25 ~1 of 0.1 M phosphate buffer, 
pH 6.1/50 mM EDTAIl % NP-40/O. 1% SDS and incubated for 
24 h at 20°C. 
ase (fig.2A). after extensive digestion with endo F, 
which cleaves the oligosaccharide component to 
give a single asparagine-linked N-acetylglucos- 
amine residue, the low, and normal-affinity anti- 
thrombins behaved identically on SDS-polyacryl- 
amide gel electrophoresis (fig.2B, lanes 6,7). 
Evaluation of the data suggested that the under- 
lying medical condition was explicable in terms of 
a point mutation, which did not involve a change in 
charge, but introduced a new partially utilised Asn- 
X-Thr/Ser carbohydrate attachment sequence. 
3.3. Peptide mapping 
Repeated SDS-polyacrylamide gel electrophore- 
sis of CNBr fragments [14] failed to show any dif- 
ferences between the low-heparin-affinity and nor- 
mal’ antithrombin fractions, despite the fact that 
control samples incubated in 70% formic acid 
alone still retained the 60.5 kDa as well as the 58 
kDa band (not shown). This served to exlude CNBr 
fragments with molecular masses greater than 7 
kDa as possible new carbohydrate sites and implied 
that the mutation was in a smaller fragment, i.e. 
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Fig.3. Reverse-phase tryptic peptide maps of carboxyamidomethylated antithrombin from the propositus. (Lower trace) 1 
affinity fraction; (upper trace) normal fraction. The peak at 27.5 min was present in all normal antithrombins analysed 
from digests of antithrombin Rouen-III. 
.ow-heparin- 
but missing 
between residues l-20, 90-103, 253-338 (four pep- 
tides generated from this region) or 424-432. 
Similarly, but not conclusively, partial cleavage at 
cysteine residues with nitrothiocyanobenzoic acid 
[15] implied that the mutation occurred before the 
second cysteine at position 22. 
Tryptic peptide mapping by reverse-phase HPLC 
gave the first definitive clue as to the location of the 
mutation site. Maps of the normal antithrombin 
fraction were essentially identical to maps of the 
low-heparin-affinity fraction except that the peak 
at 27.5 min was not present in the abnormal an- 
tithrombin (fig.3). Amino acid analysis of this 
peak (His 1.0, Gly 1.3, Ser 0.9, Pro 2.0, Val 1.0, 
Asx 0.8, Ile 1.0, CMCys 0.7, Thr 0.9, Ala 1.2, Lys 
0.8, Arg 0.9) showed that it represented the ex- 
pected 13-residue N-terminal tryptic fragment. As 
no new aberrant peak was clearly apparent in 
digests of the abnormal fraction, the native carbox- 
yamidomethylated protein was subjected to direct 
gas-phase sequence analysis. This yielded an initial 
sequence of His-Gly-Ser-Pro-Val-Asp-Asn-Cys- 
Thr-Ala-Lys-Pro-Arg-Asp-Ile-Pro-Met-Asn-Pro- 
Met-Cys-Ile-. The expected isoleucine at position 7 
was absent and replaced instead by asparagine. The 
yield of Asn 7, however, was about half that ex- 
pected considering the yield of Asn 14. This finding 
of a reduced yield of asparagine is consistent with 
partial glycosylation occurring at the new Asn-Cys- 
Thr sequence. 
4. DISCUSSION 
The pulmonary embolism suffered by the pro- 
positus during a period of heparin treatment is 
understandable in the light of the subsequent 
finding of a genetic variant of antithrombin with 
impaired heparin activation. The identification of 
the primary mutation in antithrombin Rouen-III as 
7 Ile+Asn explains its charge and molecular mass 
heterogeneity. There is no inherent alteration in 
charge or molecular mass with this substitution. 
However, the new oligosaccharide attachment se- 
quence of Asn-Cys-Thr allows for the observed 
heterogeneity of the new antithrombin. 
The decreased heparin affinity of the variant is in 
accord with the currently accepted model of the 
heparin-binding domain of antithrombin. The 
evidence from functional genetic mutants and pro- 
tein homologies indicates that the negatively 
charged heparin binds through ionic bonds to Arg 
47 of the A helix and along the outer surface of, 
and parallel to, the D helix (Lys 125, Arg 129, Arg 
132, Lys 133) [4,5]. Unfortunately, there is no 
precise information on the position of residue 7 of 
antithrombin, modelled on the three-dimensional 
structure of cur-antitrypsin. Position 7 has no 
equivalent in antitrypsin because antithrombin has 
a sequence of 25 additional amino acids at its N- 
terminus. The Cys at position 8, however, is 
disulfide bonded to Cys 128 of the D helix. This 
121 
Volume 237, number 1,2 FEBS LETTERS September 1988 
would place Ile 7 m the vicinity of the D helix, 
probably towards the N-terminal end near Arg 47 
14,519 and well within the proposed heparin- 
binding domain. Interestingly, the upper end of the 
heparin-binding domain is defined by the physio- 
logical variant, antithrombin B, which lacks an 
oligosaccharide side chain on Asn 135. The de- 
creased steric hindrance resulting from the absence 
of the carbohydrate results in an increased heparin 
affinity in this particular instance. 
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